<DOC>
	<DOCNO>NCT02193880</DOCNO>
	<brief_summary>The purpose study determine safety efficacy post-transplant cyclophosphamide post-transplant infusion donor cell , specially process remove alpha beta t-cells , patient undergo haploidentical allogeneic stem cell transplant help reduce risk relapse without increase risk graft-versus-host disease .</brief_summary>
	<brief_title>Safety Efficacy Trial Alpha-Beta Depleted T-Cell Infusions Post Haplo Transplant</brief_title>
	<detailed_description>Transplant patient participate clinical trial receive one 3 standard pre-transplant chemotherapy preparative regimen appropriate specific disease . They receive standard non-manipulated donor stem cell infusion transplant day ( day 0 ) follow cyclophosphamide ( day +3 +4 ) alpha-beta t-cell reduce donor stem cell infusion day +7 .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Neoplastic hematological disorder indication allogeneic transplant No available suitable HLAmatched donor Adequate cardiac , pulmonary , renal , hepatic function Karnofsky performance status score great equal 70 % Medication noncompliance No appropriate caregiver identify Uncontrolled medical psychiatric disorder Active central nervous system ( CNS ) neoplastic involvement Known allergy Dimethyl Sulfoxide HIV1 HIV2 positive Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>